Literature DB >> 23960897

Medical management of thyroid eye disease.

Dawn D Yang1, Mithra O Gonzalez, Vikram D Durairaj.   

Abstract

Thyroid eye disease (TED) is the most common cause of orbital disease in adults. The immunologic pathogenesis of TED has been an area of active research and considerable progress has resulted in an expansion of therapeutic options. Although surgical intervention may be required, a majority of TED patients can be managed with medical therapies. Of medical therapies, glucocorticoids remain the agent of choice in the control of TED activity. The objective of this review is to discuss the paradigm and options in medical management of TED.

Entities:  

Keywords:  Exophthalmos; Eyelid retraction; Graves’ ophthalmopathy; Thyroid eye disease; Thyroid-associated ophthalmopathy

Year:  2010        PMID: 23960897      PMCID: PMC3729509          DOI: 10.1016/j.sjopt.2010.10.001

Source DB:  PubMed          Journal:  Saudi J Ophthalmol        ISSN: 1319-4534


  123 in total

1.  Low- versus high-dose radiotherapy for Graves' ophthalmopathy: a randomized, single blind trial.

Authors:  G J Kahaly; H P Rösler; S Pitz; G Hommel
Journal:  J Clin Endocrinol Metab       Date:  2000-01       Impact factor: 5.958

Review 2.  Understanding the immunology of Graves' ophthalmopathy. Is it an autoimmune disease?

Authors:  R S Bahn
Journal:  Endocrinol Metab Clin North Am       Date:  2000-06       Impact factor: 4.741

3.  Orbital rim fat atrophy after repository periocular corticosteroid injection.

Authors:  R A Nozik
Journal:  Am J Ophthalmol       Date:  1976-12       Impact factor: 5.258

Review 4.  Relationship between Graves' ophthalmopathy and type of treatment of Graves' hyperthyroidism.

Authors:  C Marcocci; L Bartalena; F Bogazzi; G Bruno-Bossio; A Pinchera
Journal:  Thyroid       Date:  1992       Impact factor: 6.568

5.  High-dose intravenous corticosteroid therapy for Graves' ophthalmopathy.

Authors:  P E Macchia; M Bagattini; G Lupoli; M Vitale; G Vitale; G Fenzi
Journal:  J Endocrinol Invest       Date:  2001-03       Impact factor: 4.256

Review 6.  Orbital radiotherapy for Graves' ophthalmopathy.

Authors:  Luigi Bartalena; Claudio Marcocci; Maria Laura Tanda; Roberto Rocchi; Barbara Mazzi; Giuseppe Barbesino; Aldo Pinchera
Journal:  Thyroid       Date:  2002-03       Impact factor: 6.568

7.  Octreotide (long-acting release formulation) treatment in patients with graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study.

Authors:  J L Wémeau; P Caron; A Beckers; V Rohmer; J Orgiazzi; F Borson-Chazot; M Nocaudie; P Perimenis; S Bisot-Locard; I Bourdeix; S Dejager
Journal:  J Clin Endocrinol Metab       Date:  2004-11-23       Impact factor: 5.958

Review 8.  Remission of Graves' disease during anti-thyroid drug therapy. Time to reconsider the mechanism?

Authors:  Peter Laurberg
Journal:  Eur J Endocrinol       Date:  2006-12       Impact factor: 6.664

9.  Treatment of upper eyelid retraction associated with thyroid eye disease with subconjunctival botulinum toxin injection.

Authors:  Jimmy M Uddin; Peter D Davies
Journal:  Ophthalmology       Date:  2002-06       Impact factor: 12.079

10.  Long-term safety of orbital radiotherapy for Graves' ophthalmopathy.

Authors:  Claudio Marcocci; Luigi Bartalena; Roberto Rocchi; Michele Marinò; Francesca Menconi; Eugenia Morabito; Barbara Mazzi; Salvatore Mazzeo; Maria Sole Sartini; Marco Nardi; Francesco Cartei; Luca Cionini; Aldo Pinchera
Journal:  J Clin Endocrinol Metab       Date:  2003-08       Impact factor: 5.958

View more
  6 in total

1.  Update in oculoplastic imaging.

Authors:  Imtiaz A Chaudhry
Journal:  Saudi J Ophthalmol       Date:  2012-11-10

2.  Thyroid associated orbitopathy: Understanding pathophysiology.

Authors:  Imtiaz A Chaudhry
Journal:  Saudi J Ophthalmol       Date:  2010-11-11

3.  Medical management of thyroid eye disease - A paradigm shift.

Authors:  Santosh G Honavar
Journal:  Indian J Ophthalmol       Date:  2020-08       Impact factor: 1.848

4.  Low- vs. high-dose radiotherapy in Graves' ophthalmopathy: a retrospective comparison of long-term results.

Authors:  Thomas Weissmann; Sebastian Lettmaier; Anna-Jasmina Donaubauer; Christoph Bert; Manfred Schmidt; Friedrich Kruse; Oliver Ott; Markus Hecht; Rainer Fietkau; Benjamin Frey; Florian Putz
Journal:  Strahlenther Onkol       Date:  2021-04-16       Impact factor: 4.033

5.  Tocilizumab for thyroid eye disease.

Authors:  Shirin Hamed Azzam; Swan Kang; Mario Salvi; Daniel G Ezra
Journal:  Cochrane Database Syst Rev       Date:  2018-11-27

6.  Short and long-term effects of high-dose intravenous methylprednisolone pulse therapy on thyroid-associated ophthalmopathy.

Authors:  Xiaomei Liu; Shu Wang; Li Qin; Wei Qiang; Mahesh Dahal; Ping Fan; Shan Gao; Bingyin Shi
Journal:  Exp Ther Med       Date:  2016-06-09       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.